Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Patients testing a new weight-loss drug developed by the creators of Ozempic have revealed the extreme effects it had on their bodies. Danish pharma giant Novo Nordisk has been tight-lipped ...

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...

Both Ozempic ... the maximum dose of CagriSema, while the remaining 40% were on lower doses. 40% of patients achieved a weight loss of 25% or more. This suggests (although Novo Nordisk hasn ...